BR
BRSYF
Brainsway Ltd.
$16.84
0.00%
No data for this timeframe.
Vol
SEC Reports5
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. L3·CIK 0001505065·Prev Close $16.84
Recent Activity
Jun 9, 2026
SEC
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at the CTMSS annual meeting
6-K — Impact 7/10
May 18, 2026
SEC
BrainsWay announced a minority-stake investment of $1.5 million (with potential for an additional $1.5 million via miles
6-K — Impact 4/10
May 13, 2026
SEC
BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and net income of $2.3 million (up >100% YoY), with Adj
6-K — Impact 8/10
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Latest Reports
BULLISH
6-K
7/10
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at the CTMSS annual meeting
Jun 9, 2026
NEUTRAL
6-K
4/10
BrainsWay announced a minority-stake investment of $1.5 million (with potential for an additional $1.5 million via miles
May 18, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.6/10.
BULLISH
6-K
7/10
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at the
Jun 9, 2026
NEUTRAL
6-K
4/10
BrainsWay announced a minority-stake investment of $1.5 million (with potential for an additional $1
May 18, 2026
BULLISH
6-K
8/10
BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and net income of $2.3 million (up
May 13, 2026
BULLISH
20-F
7/10
Brainsway's 20-F filing for 2025 shows strong financial growth with a 27% revenue increase to $52.2
Apr 20, 2026
BULLISH
6-K
7/10
Brainsway highlighted expanding U.S. payer coverage allowing nurse practitioners to administer its D
Apr 15, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 29.1% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 28.4% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 28.6% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 23.1% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.